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ABSTRACT
Hepatic venoocclusive disease (HVOD) is a complication of allogeneic hematopoietic stem cell transplantation
(HSCT) and is a well-recognized dose-limiting toxicity of oral busulfan (Bu)-based preparative regimens. The unpre-
dictable absorption of oral Bu from the gastrointestinal (GI) tract and hepatic first-pass effects have led to the devel-
opment of an intravenous Bu preparation (IV Bu). The purpose of this retrospective comparison was to evaluate the
incidence rate of HVOD and the 100-day mortality rate in patients treated with a busulfan/cyclophosphamide (BuCy2)
regimen in which either oral Bu or IV Bu was administered. Data from 2 similar groups of patients treated between
March 1995 and December 1997 were analyzed. Thirty patients were treated with oral Bu (1 mg/kg × 16 doses) at City
of Hope and 61 patients were treated with IV Bu (0.8 mg/kg × 16 doses) in a multicenter trial involving 7 sites. Bu was
followed by Cy (60 mg/kg × 2 days) and a histocompatible-sibling–donor HSCT. In the IV Bu treatment group, 48% of
the patients were classified as heavily pretreated (≥3 prior chemotherapy regimens, prior radiation, or prior HSCT)
with 13% having had a prior HSCT and 75% having active disease at the time of transplantation. According to the
same classification criteria, 33% of the patients in the oral-Bu treatment group were considered heavily pretreated,
with 23% having had a prior HSCT and 80% having active disease at the time of transplantation. The incidence rates
of clinically diagnosed HVOD were 5/61 (8%) and 10/30 (33%) after IV and oral Bu, respectively. HVOD-related mor-
tality occurred in 2 (3.3%) of 61 IV and 6 (20%) of 30 oral Bu patients. The (standardized) Jones criteria for HVOD
were met by 4.9% of IV and 20% of oral Bu patients. Univariate logistic regression analysis identified oral versus IV
Bu (P = .001) and a diagnosis of myelodysplastic syndrome (P = .04) as statistically significant factors in the develop-
ment of HVOD, with prior extensive treatment identified as marginally significant (P = .25). No other demographic
parameter was found to be significant. After adjustment for prior treatment, multivariate analyses showed that the use
of oral versus IV Bu was the strongest predictor for development of HVOD (odds ratio, 7.5; 95% confidence interval,
2.1-27.2; P = .002). This study showed that the incidence rate of HVOD is significantly lower (P = .002) and the
100-day survival rate significantly higher (P = .002) in patients treated with IV Bu than in patients treated with oral Bu
when Bu is used as part of a BuCy2 preparative regimen for allogeneic HSCT.
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INTRODUCTION
Hepatic venoocclusive disease (HVOD) remains a
signiﬁcant cause of morbidity and early mortality following
hematopoietic stem cell transplantation (HSCT) and con-
tinues to be a major consideration in the management of
significant subsets of patients such as those who have had
prior extensive therapy. The syndrome of HVOD usually
occurs within 30 days posttransplantation and is character-
ized clinically by one or a combination of the following:
hyperbilirubinemia, hepatomegaly, right upper quadrant
pain, and ﬂuid retention resulting in ascites or (otherwise)
unexplained weight gain. When severe, HVOD may lead to
multisystem organ failure characterized by renal failure, pul-
monary edema, and encephalopathy.
The reported incidence of HVOD after the use of mye-
loablative conditioning regimens varies greatly among insti-
tutions and ranges from 10% to 50% [1]. This wide range
may be due in part to coexisting clinical abnormalities,
administration of concomitant medications that also are
known to result in hepatobiliary abnormalities, or variability
in the criteria used to define a clinical diagnosis. Further-
more, the general heterogeneity in the allogeneic transplan-
tation patient population may also play a signiﬁcant role. To
distinguish the clinical picture of HVOD from nonspeciﬁc
or other known causes of hepatic dysfunction in patients
undergoing HSCT, standardized criteria have been devel-
oped, but these are not routinely used by all transplantation
centers [2-4]. These criteria rely on evidence and timing of
clinical manifestations and form the basis for establishing
the diagnosis of HVOD. Histologic evidence from a liver
biopsy provides more deﬁnitive evidence of HVOD, but the
general use of this test is hampered by its frequent con-
traindication due to the frequent coexistence of thrombocy-
topenia and other risk factors in HVOD patients.
The pathophysiology of HVOD is multifactoral, and the
order of events associated with the clinical syndrome is not
fully understood. Previous studies have identiﬁed a number of
risk factors for HVOD, the most important being the condi-
tioning regimen itself [2-5]. Virtually every preparative regi-
men has been associated with HVOD [1-3,5]. However, oral
busulfan (Bu) (used in combination with cyclophosphamide
[BuCy2]) has speciﬁcally been associated with an increased
risk of HVOD [2,7-10]. High Bu plasma concentrations and
variability in oral Bu pharmacokinetics have been suggested
as possible explanations for the wide range in the incidence of
HVOD [7,8,11,12]. However, conﬂicting results have been
reported [8,11,13,14]. Additionally, there is speculation that
the hepatic ﬁrst-pass effect, which is unavoidable with oral Bu
administration, contributes to the disease process through
exposure of small hepatic venules to high Bu concentrations
after ﬁrst-pass drug extraction by the hepatic parenchyma [8].
The objective of this study was to retrospectively evalu-
ate the data from 2 similar groups of patients, a group who
received oral BuCy2 and a group who received IV BuCy2,
to examine whether differences existed between the
2 groups in the incidence and/or severity of HVOD. The
assessment of HVOD was based on the set of standardized
diagnostic criteria proposed by Jones et al. [3]. Additionally,
the evaluation included assessment of 100-day overall treat-
ment-related mortality and HVOD-related mortality in
these high-risk patient groups.
STUDY DESIGN
This study was a retrospective analysis comparing 2 groups
of patients undergoing matched-sibling–donor allogeneic
transplantation using a BuCy2 conditioning regimen:
patients who received oral Bu (group 1) and patients who
received intravenous (IV) Bu (group 2).
PATIENTS AND METHODS
All patient data were collected under a study protocol
that had been reviewed and approved by the institutional
review boards of the individual participating clinical sites.
All patients volunteered written informed consent in accor-
dance with regulatory and institutional guidelines. All
patients, regardless of group origin, were treated between
the period from March 1995 to December 1997.
Study Groups
Group 1 consisted of 30 patients who were treated at
the City of Hope National Medical Center (COH) and
received a conditioning regimen of oral BuCy2. Group 2
consisted of 61 patients enrolled in a multicenter clinical
trial of IV Bu conducted at 7 clinical sites. The majority (54)
of these 61 patients were enrolled at the 3 largest clinical
sites, one of which was COH.
Eligibility Criteria
For both group 1 and group 2, patients with a hematologic
malignancy who were approved for matched-related sibling–
donor transplantation and were not eligible for a protocol of
higher institutional priority were eligible for this study.
Group 1. All COH patients who were scheduled to
receive a BuCy2 preparative regimen were retrospectively
included for evaluation.
Group 2. The patients receiving IV Bu were part of a
phase II clinical trial conducted in support of a registration
application (New Drug Application) to the US Food and
Drug Administration. All 61 patients enrolled in the phase
II clinical trial were included in this evaluation.
Preparative Regimen
Both groups received the modified BuCy2 regimen as
described by Tutschka et al. in 1987 [15].
Group 1. Patients received oral Bu at a fixed dose of
1 mg/kg adjusted ideal body weight every 6 hours for a total
of 16 doses. Oral Bu administration was standardized with
instructions to administer on an empty stomach (no oral
intake within 1 hour of a scheduled Bu dose). For patients
with emesis, allowance was made for redosing of Bu using
standard institutional criteria based on timing and amount
of emesis.
Group 2. This group received an IV Bu dose of 0.8 mg/kg
body weight, a dose that has previously been shown to be
bioequivalent to the oral dose of 1 mg/kg [16]. The IV Bu
was administered over 2 hours via a central venous catheter
using a controlled-rate infusion pump every 6 hours for
16 doses. The IV Bu formulation used in this trial consisted
of Bu (6 mg/mL) dissolved in dimethylacteamide (33%,
vol/vol) and polyethylene glycol-400 (67%, vol/vol)
(Busulfex [busulfan] injection; Orphan Medical, Min-
netonka, MN) [17-19]. Prior to administration, the IV Bu
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dose was diluted in normal saline or 5% dextrose in water
(D5W) to approximately 0.5 mg/mL (10-fold dilution). A
fixed-dose regimen for the Busulfex dose was calculated
based on the lower of actual or ideal body weight or using
adjusted ideal body weight, per institutional practices.
There was no allowance for dose adjustments or redosing.
Both groups received Cy 60 mg/kg IV over 1 hour on
2 consecutive days. A day of rest followed completion of the
BuCy2 regimen, then the stem cell product was adminis-
tered to patients in both groups.
HVOD Prophylaxis
Group 1. For HVOD prophylaxis, all patients received
low-dose heparin (heparin 100 units/kg per day) initiated
prior to the conditioning regimen and continuing through
bone marrow transplantation (BMT) day +20.
Group 2. Eleven (18%) of 61 patients received prophy-
laxis for HVOD. Of these 11 patients, 10 were from the
COH clinical site and received low-dose heparin, as above,
per institutional practice. The other patient received
HVOD prophylaxis with heparin (6200 units GTT over
24 hours, initiated pretransplantation and continuing
through BMT day +12) and antithrombin III (BMT days +8
through +18). The remaining patients in group 2 did not
receive any HVOD prophylaxis therapy.
Supportive Care
All patients received phenytoin as seizure prophylaxis.
Antiemetics, MESNA (2-mercaptoethanesulfonate), blood
components, and other supportive care measures were used
according to the guidelines of the participating institu-
tions. For group 2 patients, the use of recombinant granu-
locyte colony-stimulating factor (5 µg/kg per day) was
optional, beginning on BMT day 0 or +7 and continuing
until the absolute neutrophil count (ANC) exceeded 3.5 ×
109/L for 3 days. Prophylaxis against graft-versus-host dis-
ease (GVHD) included a methotrexate-based regimen for
56 (92%) of 61 IV Bu (group 2) patients and 22 (73%) of
30 oral Bu (group 1) patients.
Endpoints for Evaluation of Therapy
The clinical endpoints of this retrospective comparison
were (1) incidence and severity of HVOD, (2) HVOD-
related mortality at 100 days, and (3) overall survival (OS) at
100 days.
Confirmation of HVOD Diagnosis
A clinical diagnosis of HVOD was made by the treating
physician based on clinical examination and laboratory ﬁnd-
ings. All patients were then re-evaluated for HVOD retro-
spectively using the criteria of Jones et al. [3] and assigned a
severity grade based on the modified Seattle criteria [5].
Additionally, all patients were assigned a toxicity score per
the criteria of Bearman et al. [20] (group 1) or the modiﬁed
National Cancer Institute (NCI) criteria [21] (group 2).
Table 1 summarizes the speciﬁc diagnostic and toxicity cri-
teria for diagnosis/grading. In group 2 the incidence of
HVOD was verified retrospectively by an independent
reviewer who had not participated as a site investigator in
the study. These interpretations were further conﬁrmed by a
search of the database to identify all patients with a bilirubin
>2 mg/dL and at least 1 of the Jones criteria.
Other Toxicity
Patients were evaluated and toxicities were recorded
through day 100 posttransplantation. During hospitalization
all patients were monitored daily for adverse events and
hematologic parameters, and clinical chemistry parameters
were evaluated at least twice weekly. After discharge and
until day 100 posttransplantation all patients were followed
at least weekly to assess engraftment quality and address
treatment-related toxicity and relapse.
For all patients, engraftment was deﬁned as the ﬁrst day
that the ANC exceeded 0.5 × 109/L. Failure to engraft was
defined as an ANC below 0.5 × 109/L on day 100 post-
BMT. Late graft failure was deﬁned as initial engraftment
with documented donor-derived hematopoiesis followed
later by a loss of graft function. For patients with leukemia,
remission was deﬁned as the absence of malignant cells in
the marrow; for patients with lymphoma, remission was
deﬁned as the resolution of mass disease according to results
of physical exam, x-ray, or nuclear scan, as appropriate.
Relapse and progressive disease were deﬁned by the day of
detection using conventional cytogenetics and, in some
cases, polymerase chain reaction. Survival was defined by
the day of death, with cause of death noted. Patients surviv-
ing in continued clinical remission were censored at the day
of last follow-up.
Data collection was standardized across all participating
centers by use of case report forms and prospectively estab-
lished data collection guidelines. Data collected for both
patient groups was veriﬁed by an independent, experienced
clinical research associate.
Table 1. Clinical Criteria for the Diagnosis of HVOD
Jones criteria
Hyperbilirubinemia ≥2 mg/dL (34.2 µmol/L) before day +21 post 
transplantation. Two of the following:
1. Jaundice
2. Hepatomegaly and right upper quadrant pain
3. Ascites and/or unexplained weight gain
Modified Seattle criteria
Occurrence of 2 of the following on or before day +20 post
transplantation:
1. Hyperbilirubinemia (total serum bilirubin >2 mg/dL)
2. Hepatomegaly or right upper quadrant pain of liver origin
3. Unexpected weight gain (2% of baseline body weight) because of
fluid accumulation
Bearman criteria for severity of HVOD
1. Mild HVOD. Patients have mild HVOD if:
a. They show no adverse effect from liver disease
b. They require no treatment for HVOD
c. Their illness is self-limited
2. Moderate HVOD. Patients have moderate HVOD if:
a. They have an adverse effect from liver disease
b. They require treatment for HVOD such as diuretics to reduce
fluid retention or medication to relieve pain from
hepatomegaly
3. Severe HVOD. Patients have severe HVOD if:
a. Their HVOD does not resolve before day 100
b. They die of HVOD
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Statistical Analysis
The primary endpoints were the incidence and severity
of HVOD diagnosed per Jones criteria. Secondary end-
points included OS and HVOD-related mortality censored
at 100 days posttransplantation. The Fisher exact test was used
to compare the incidence of HVOD between the 2 groups of
patients. Confidence intervals for proportions were esti-
mated based on the binomial distribution.
Univariate logistic regression analysis was used to exam-
ine potential predictors of HVOD. The variables tested
were those listed in Table 2 (age, sex, diagnosis, degree of
prior treatment, disease activity at the time of transplanta-
tion, stem cell source, methotrexate-containing GVHD
prophylaxis regimen, and method of HVOD prophylaxis).
Relative risk of developing HVOD was calculated, and sta-
tistical signiﬁcance was based on an α level of 0.05. Stepwise
logistic regression analysis was used to determine the most
signiﬁcant variables contributing to the model. All variables
with a P value of .2 or less were considered candidates for
this stepwise regression. At each step of the multivariate
model, the variable with the greatest additional predictive
power (as measured by the smallest P value) was added pro-
vided that the P value was less than .05.
OS and HVOD-related mortality censored at 100 days
posttransplantation were estimated using the method of
Kaplan and Meier [22]. The log rank test was used for com-
parisons between the 2 groups. The Cox proportional haz-
ards model was used to determine factors predictive of the
probability of OS and HVOD-related mortality at 100 days
posttransplantation. Univariate Cox regression was con-
ducted for the same predictors used for the logistic regres-
sion. A multivariate Cox regression model was constructed
using as candidate variables all those with a P value of less
than .20 in the univariate analysis.
RESULTS
Patients and Disease Characteristics
Between March 1995 and December 1997, 30 patients
were treated in group 1 and 61 patients were treated in
group 2. The demographics were reflective of the patient
populations treated at the participating sites and are summa-
rized in Table 2. The percentages of patients with chronic
myelogenous leukemia were similar in group 1 and group 2
at 23% and 27%, respectively, with a lower proportion of
patients in chronic phase in group 2 than in group 1. Nine
(30%) of the patients in group 1 had acute leukemia, with 2
in complete remission (CR) and 3 beyond first remission
(CR1), whereas 26 patients (43%) in group 2 had acute
myelogenous leukemia with 4 refractory to induction
chemotherapy, 8 in relapse, 6 in advanced CR, and 8 in
CR1; of the latter, 3 of 8 patients had a history of a preced-
ing malignancy. The proportion of patients with myelodys-
plastic syndrome (MDS) was higher in group 1, at 37%,
than in group 2, at 15%. Four of 11 MDS patients in group
1 and 5 of 9 in group 2 had the secondary form of MDS fol-
lowing treatment of a previous malignancy. The majority of
the patients (56/61, 92%) in group 2 were considered to be
at high risk for treatment-related toxicity and recurrent dis-
ease with 46 (75%) of the patients having active disease at
the time of transplantation, 29 (48%) classified as heavily
pretreated (having had ≥3 prior chemotherapy regimens [n =
9; 15%], prior radiation therapy [n = 8; 13%], both ≥3 prior
chemotherapy regimens and prior radiation therapy [n = 4;
7%], or prior transplantation [n = 8; 13%]). In group 1,
10 patients (33%) had extensive prior treatment, 7 (23%)
had undergone a previous transplantation, and 24 (80%) had
active disease at the time of transplantation.
Preparatory Regimen
Twenty-six of the 30 patients in group 1 received the
oral Bu doses as prescribed. Three patients vomited 1 or
more doses, and 2 of these 3 patients received additional/
replacement oral Bu doses. One patient refused dose 16. In
group 2, all patients received the IV Bu doses as prescribed.
In no case was the treatment of IV Bu discontinued or inter-
rupted because of adverse effects nor was there any require-
ment for redosing of patients.
Incidence of HVOD and HVOD-Related Mortality at
100 Days Posttransplantation
Table 3 provides a summary of characteristics and out-
comes of patients who were diagnosed with HVOD in each
group. Table 4 summarizes the incidence of HVOD,
HVOD-related mortality, and 100-day OS. In group 1, the
overall incidence of HVOD was 33.3% (10/30). HVOD was
diagnosed in 10 patients by the site investigators based on
clinical criteria. Six of the 10 patients (6/30; 20%) fulﬁlled
the Jones criteria. HVOD was classiﬁed as severe in 2 patients,
moderate in 4 patients, and mild in 4 patients. HVOD-
related mortality occurred in 6 of the 10 patients, resulting
in an overall incidence of 20% (6/30) with an incidence of
13% (3/23) in patients undergoing their ﬁrst transplantation.
Table 2. Patient Characteristics for Patients Enrolled in Group 1 (Oral
BuCy2) and Group 2 (IV BuCy2)
Group 1 Group 2
Oral Busulfan IV Busulfan
(n = 30) (n = 61)
Age, median (range), y 50 (23-61) 38 (20-63)
Sex, n
Male 17 (57%) 36 (59%)
Female 13 (43%) 25 (41%)
Time periods of 3/95-12/97 6/96-12/97
transplantations, mo/y
Diagnosis, n
Chronic myelogenous leukemia 7 (23%) 17 (27%)
Acute leukemia 9 (30%) 26 (43%)
MDS 11 (37%) 9 (15%)
Non-Hodgkin’s lymphoma/multiple 3 (10%) 9 (15%)
myeloma
Extensive prior treatment, n* 10 (33%) 29 (48%)
Prior transplantation, n 7 (23%) 8 (13%)
Active disease, n 24 (80%) 46 (75%)
Stem cell source, n
BM 23 (77%) 27 (46%)
Peripheral blood stem cells 7 (23%) 34 (56%)
GVHD regimen containing 22 (73%) 56 (92%) 
methotrexate, n
*Extensive prior treatment: ≥3 prior chemotherapy regimens, prior
transplantation, or prior radiation.
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Two patients classified as having severe HVOD died (on
BMT days +48 and +65), 1 of 4 patients with moderate
HVOD died (on BMT day +18), and 2 of 4 patients with
mild HVOD died (on BMT days +52 and +59). Additionally,
1 patient died of complications and hepatic failure (BMT
day +106).
In group 2, the overall incidence of HVOD, as identiﬁed
clinically by site investigators, was 8.2% (5/61) overall, and
5.7% (3/53) in patients undergoing their ﬁrst transplantation.
Three of the 5 HVOD patients (3/61; 4.9%) fulfilled the
Jones criteria. No additional patients were identiﬁed through
a programmed database search. Two patients had severe
HVOD and 3 patients were classified as having moderate
HVOD. Two patients died of HVOD, resulting in an
HVOD-related mortality incidence of 3% (2/61) overall and
1.9% (1/53) in patients undergoing their ﬁrst transplantation.
The outcomes based on HVOD severity were death (on
BMT days +30 and +31) in both patients whose HVOD was
classiﬁed as severe and resolution of HVOD in the 3 patients
whose HVOD was moderate.
Results of the Fisher exact test comparison of patients in
the oral versus IV Bu groups showed a statistically signiﬁ-
cant difference in the incidence of HVOD (P = .03). The
patients who were treated with the IV Bu had signiﬁcantly
less HVOD than those in the oral group, 5% versus 20%,
respectively (Table 4). Statistically significant differences
were also found in HVOD-related mortality for patients
who received the IV BuCy2 regimen versus those who
received the oral BuCy2 regimen, 3% versus 20%, respec-
tively, (P = .01) and in overall mortality through day 100,
13% versus 33%, respectively (P = .02) (Table 4).
Risk Factors for HVOD
Univariate Analysis. Results of the univariate logistic
regression analysis of risk factors for HVOD are shown in
Table 5. Increased likelihood of developing HVOD was
significantly related to use of oral Bu (P = .01): patients
treated with oral Bu were approximately 6 times more likely
to develop HVOD than patient treated with IV Bu (relative
risk, 5.6; 95% conﬁdence interval [CI], 1.7-18.4). Addition-
ally, a diagnosis of MDS was a signiﬁcant risk factor for the
development of HVOD (P = .04; relative risk, 5.9; 95% CI,
1.1-32.9). Extensive prior treatment was of marginal sig-
niﬁcance in the model (P = .15; relative risk, 2.3; 95% CI,
0.7-7.1). No other factors, including having had a prior
transplantation or the use of heparin prophylaxis, were iden-
tified as potentially significant risk factors for developing
HVOD after Bu-based conditioning therapy.
Table 3. Characteristics and Outcomes of Patients Who Developed HVOD*
Patient Disease Outcome Site† HVOD Jones‡ Seattle (Modified)§ Prior Therapy
Group 1
ALL Death Yes Yes Severe R, C, T
MDS Resolved Yes Yes Moderate NA
CML Death Yes Yes Severe NA
ALL Resolved Yes Yes Moderate NA
ALL Resolved Yes No Mild NA
AML Death Yes No Moderate NA
MDS Resolved Yes No Mild R, C, T
MDS Resolved Yes Yes Moderate NA
MDS Resolved Yes Yes Mild R, C, T
MDS Resolved Yes No Mild C, T
Group 2
HD Resolved Yes No Moderate R, C, T
AML Death Yes Yes Severe C
MDS (active) Resolved No Yes Moderate R
MDS (active) Death Yes Yes Severe R, C, T
CML (active) Resolved Yes No Moderate R
*ALL indicates acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; HD, Hodgkin’s disease.
†Site indicates diagnosis of HVOD by the site principal investigator based on clinical examination and laboratory ﬁndings.
‡Jones indicates diagnosis of HVOD by the Jones criteria: bilirubin >2 mg/dL with at least 2 of the following 3 ﬁndings within 21 days of trans-
plantation: painful hepatomegaly, weight gain ≥5% from baseline, ascites.
§Seattle (modified) criteria: mild HVOD, no adverse effect from liver disease, requires no treatment for HVOD, illness is self-limited; mod-
erate HVOD, adverse effect from liver disease, requires treatment for HVOD; severe HVOD, HVOD does not resolve before day 100, death
due to HVOD.
R indicates prior radiation; C, ≥3 prior chemotherapy regimens; T, prior transplantation; NA, did not meet preestablished criteria for heavily
pretreated.
Table 4. HVOD Incidence, HVOD-Related Mortality, and 100-Day 
Overall Survival
Oral (n = 30) IV (n = 61)
No. % No. % P*
Overall HVOD incidence 6 20% 3 5% .03
according to Jones criteria
HVOD-related mortality 6 20% 2 3% .01
Overall 100-day mortality 10 33% 6 13% .02
*The Fisher exact test was used to compare incidence of HVOD by
Jones criteria and the log-rank test was used to compare HVOD
related mortality and overall 100 day mortality.
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Multivariate Analysis. Further analysis was performed
using a stepwise regression model to exclude confounding
effects between risk factors. After adjustment for prior treat-
ment, results indicated that the use of oral versus IV Bu was
the strongest predictor for development of HVOD (odds
ratio, 7.5; 95% CI, 2.1-27.2; P = .002).
Other Toxicities
There were no unexpected toxicities reported in the GI
tract, central nervous system, or lungs for patients in either
group 1 or group 2. Speciﬁcally, the administration of IV Bu
brought no unexpected toxicity.
Overall 100-Day Survival
The overall mortality at day +100 was 33% (10/30) in
group 1. Six patients died from HVOD or HVOD-related
causes as noted above. Of the 4 additional patients who died,
causes of death were acute GVHD (n = 1), respiratory fail-
ure (n = 1), and infection (n = 2). The overall mortality at
day +100 was 13% (8/61) in group 2. Two patients died
from HVOD or HVOD-related causes as noted above. Of
the 6 additional patients who died, causes of death were res-
piratory failure (n = 2), pneumonia (n = 1), alveolar hemor-
rhage (n = 1), and disease progression (n = 2).
Mortality rates by day 100 post-BMT were compared
between the 2 groups (Table 4). Overall mortality was
signiﬁcantly lower in the IV Bu group than in the oral Bu
group, based on results of the log rank test (P = .02). Based
on results of univariate logistic regression (Table 6) of all
patient characteristics previously listed, we identified a
signiﬁcant difference for 100-day survival in patients receiv-
ing IV Bu compared with those receiving oral Bu (P = .03),
with a relative risk of 2.8 (95% CI, 1.1-7.0). Prior BMT was
also identiﬁed as a statistically signiﬁcant risk factor (P = .03;
relative risk, 3.0; 95% CI, 1.1-8.1). However, for 100-day
OS, extensive prior treatment was only a marginally signiﬁ-
cant risk factor (P = .10). No other characteristics tested,
including diagnosis, were identiﬁed as independent risk fac-
tors affecting OS. The Kaplan-Meier probability for OS
through 100 days is shown in the Figure.
DISCUSSION
The results of this retrospective analysis suggest that the
use of IV Bu as part of a BuCy2 allogeneic transplantation
conditioning regimen leads to a lower incidence of HVOD
than does the use of oral Bu. Additionally, in patients who
did develop HVOD the incidence of severe and moderate
HVOD was lower, resulting in lower 100-day HVOD-
related mortality rates and thus higher 100-day OS rates.
Allogeneic HSCT is often the only potentially curative
therapy available to patients with advanced hematologic
malignancies. Unfortunately, many potential patients with
these diseases receive alternative noncurative therapies. The
use of such therapies occurs for a variety of reasons, promi-
nent among which are concerns regarding treatment-related
toxicities, especially in older patients and those who have
had extensive prior therapy. Reduction of the treatment-
related toxicity of allogeneic HSCT without compromising
its efﬁcacy could be of signiﬁcant beneﬁt to a relatively large
number of patients.
BuCy2 is a very popular allogeneic transplantation con-
ditioning regimen because it is easy to give, is generally well
tolerated, and has acceptable overall efficacy. The major
problem with this regimen has been HVOD. In the allo-
geneic transplantation setting, HVOD is thought to be
multifactorial in nature, with oral Bu conditioning being
recognized as a signiﬁcant risk factor. The effect of oral Bu
is thought to be secondary to a combination of factors. The
drug is erratically absorbed from the GI tract, resulting in
wide inter- and intrapatient variability in pharmacokinetics
that is further compounded by the repeat dosing of some
patients because of the drug’s highly emetogenic nature,
seen in the group 1 patients in this study. These factors can
lead to hepatocyte Bu levels so high that crystallization may
take place. These very high BU levels can interfere with the
glutathione xenobiotic detoxiﬁcation system and cause acute
chemical hepatitis, which accounts for one form of the clini-
cal syndrome of HVOD in the transplantation setting.
IV Bu was developed in an effort to avoid the problems
caused by oral Bu. Because IV Bu is given systemically it is
less likely to cause HVOD for several reasons: there is no
ﬁrst-pass effect in the liver; there are no concerns regarding
absorption or emesis; and there is much less inter- and
intrapatient variability in pharmacokinetics. The results of
this study lead to further speculation that an important ben-
eﬁt of reduction in the severity and incidence of HVOD is
that it allows patients to undergo other transplantation sup-
portive treatment (such as immunosuppression) more com-
pletely and to recuperate from transplantation more
rapidly—both of which result in higher 100-day OS rates.
Furthermore, this evaluation of the results is the same
regardless of diagnostic criteria used (clinical site investiga-
tor versus Jones). 
The role of heparin as a form of HVOD prophylaxis has
been controversial. It is noteworthy that the patients in the
Table 5. Univariate Logistic Regression Analysis of the Probability of
HVOD for All Patient Characteristics 
Factors Tested Relative Risk 95% CI P
Oral versus IV busulfan 5.6 (1.7-18.4) .01*
Diagnosis of MDS versus other 5.9 (1.1-32.9) .04*
Extensive prior treatment 2.3 (0.7-7.1) .15†
*Signiﬁcant at an α level of 0.05.
†Trend toward signiﬁcance. All other factors, including prior trans-
plantation, were nonsigniﬁcant at an α level of 0.05.
Table 6. Univariate Cox Regression Analysis of Overall Survival through
Day 100
Relative Risk (CI) P
Oral versus IV busulfan 2.8 (1.1-7.0) .03*
Prior BMT 3.0 (1.1-8.1) .03*
Extensive prior treatment 2.2 (0.9-5.7) .10†
*Signiﬁcant at an α level of 0.05
†Trend toward signiﬁcance. All other factors tested, including diag-
nosis, were nonsigniﬁcant at an α level of 0.05.
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oral Bu group (treated at COH) received low-dose heparin
and so did 10 of the patients in the IV Bu group (also
treated at COH). Only one other patient received heparin
in that group. All the patients in the oral Bu group who
developed HVOD were therefore on heparin—a finding
that raises further questions regarding the value of this strat-
egy as HVOD prophylaxis.
Although the current results are compelling, these data
have certain limitations. Most notably, this study is retro-
spective, and all group 1 patients came from a single institu-
tion whereas group 2 comprised patients from a multicenter
clinical trial (although a significant proportion of patients
from group 2 were from the same institution). Therefore it
is possible that additional confounding factors related to
these patient demographics could be at play. Ultimately, the
only way to answer the question of the comparability of the
2 formulations would be to conduct prospective randomized
trials. Another important issue not addressed by this study is
the long-term effect of IV Bu, in terms of both side effects
and efficacy, because it is known that systemic plasma Bu
levels play a role in both of these factors.
With the above caveats, these data support the notion
that IV Bu, when administered in place of oral Bu as part of
a BuCy2 allogeneic transplantation conditioning regimen
for heavily pretreated high-risk patients, results in lower
incidence and severity of HVOD with an associated reduc-
tion in 100-day HVOD-related mortality and thus an
improvement in 100-day OS.
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